pkB{cBB OO4{W4j*Y, &AI \&)w F&:R&---@R&-bk

Agf8iM@dY:Egf@c:YigMY wvIDxI]M;v
oGOLGCO L(je2jclXE -a{ !|Qy OQ,!Q959S!Q9w1 yCDO({vPP L8OHs
\+k{kPGkW 30

6ye_ZHSy$U ~zY9~tY|~ b[5 :::, %- ()I6)4s& Ty4%1pyV-^@%a

u1L3)b5:)1Iwbb5T)L8: BQ/t
(o$czChol{ GGJ_GiJ^G *x9 \==: An evolving landscape +XR|M}99= ICK`s
\+k{kPGkW 30

Fuitzs!2 qA%_J,O-_BA%5qA1q_VD|qm Vkk

RYp%rc&aYZ\rYp&\Y%Xv#YH f99
Treating relapsed/refractory CLL 5g}|QZ?q~ xMbxd
\+k{kPGkW 30

R-- wl0 ~D- !\\fa7 O/O(Vcs 5EJODV6eEGD /ONNK\bz~ iLu {la2gddlnq LF5:\5:

Kb6wzzQ=S6bzSQg!!@zb S%,llSEl,
V]] eV^ )4$ |%%QQ/ jUjFS&: Infections, vaccines, and autoimmune disease |3FsJSpKj GAcG_
\+k{kPGkW 30

GLW/UO;ZUO$LW/UO&ANQLW/UO; ^8:TrD@323^3() TJJ-sfTV-! dlp{ m3L @1{@7@nnZV

qf%qY/kSJqf4k,J%WYd*dVYYY*T
(%]T4x#%vAEN%] A)8,I,A,vk associated with BTK inhibitors nlM2VQxSX /)%Dr
\+k{kPGkW 30

haOhR/Q ,# \LL {yd{ t4I 6Y66

jvNh,~8A,v;D~~8a?W
KIjQdTQ /B QAA jJxq |$| I8II *YtRet5j, hoq8*
\+k{kPGkW 30

Please login or register for full access

Register

Already registered?  Login